BrightInsight vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
BrightInsight is the leading global regulated digital health platform for biopharma and medtech; raised $166M total (Series C $101M led by General Catalyst in 2021); supports SaMD, connected devices, and disease management programs.
About
BrightInsight is a digital health infrastructure company that provides the leading global regulated platform for biopharma and medtech companies building Software as a Medical Device (SaMD) and connected health programs. Founded in 2017 by Kal Patel, a former Bristol-Myers Squibb executive, BrightInsight is headquartered in San Jose, California. The company's platform captures, transmits, and analyzes data from FDA-regulated and CE-marked medical devices, combination products, digital therapeutics, and companion apps — all while maintaining compliance with HITRUST, GDPR, FDA 21 CFR Part 11, IEC 62304, and other regulatory frameworks. This regulated-by-design infrastructure layer eliminates the need for biopharma and medtech companies to build compliant digital health backends from scratch.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.